Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NM8074 in Immunoglobulin A Nephropathy (IgAN)
NCT06454110Phase 2Not yet recruiting
- Sponsor
- NovelMed Therapeutics
- Start
- Feb 2028
- Primary completion
- Dec 2030
- Modality
- Monoclonal Antibodies
01
Overview
Phase 2, open-label, single-arm trial of ruxoprubart in IgA nephropathy (IgAN), sponsored by NovelMed Therapeutics. Primary endpoint: Urine Protein to Creatinine Concentration Ratio at Day 99. Planned start Feb 2028; status: not yet recruiting.
02
Drugs
ruxoprubart
03
Conditions
IgA nephropathy (IgAN)
Beyond the preview
Go deeper on NCT06454110.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06454110.